TNF Pharmaceuticals holds investor call on Isomyosamine R&D progress

Q/C TECHNOLOGIES, INC.

Conference call conducted March 6, 2025 to discuss research and development of lead compound Isomyosamine.
Transcript furnished as Exhibit 10.1; no specific clinical or financial data provided in the available text.
Company noted it undertakes no obligation to update the materials.

item 7.01 item 9.01

Q/C TECHNOLOGIES, INC. filing history →

Source: SEC EDGAR

accession 0001493152-25-009717

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.